APSR2026-192

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-003
P03
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1213351-46904-APSR_2026_COPD_Eosinophilia_Updated_Poster_A0_431252.pdf
Format: PDF Only
07. COPD
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

SUNN REN TEE * HOSPITAL QUEEN ELIZABETH RESPIRATORY DEPARTMENT KOTA KINABALU Malaysia
HEMA YAMINI DEVI A/P RAMARMUTY - HOSPITAL QUEEN ELIZABETH RESPIRATORY DEPARTMENT KOTA KINABALU Malaysia
Kunji Kannan A/L Sivaraman Kannan - HOSPITAL QUEEN ELIZABETH RESPIRATORY DEPARTMENT KOTA KINABALU Malaysia
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
SUNN REN
TEE
sunnrentee91@gmail.com
+60183632907
31-40
Malaysia
Original Research
Prevalence and persistence of blood eosinophilia in COPD: Real-world data from Sabah, Malaysia
Maximum 25 words
Abstract Content
Blood eosinophil count (BEC) guides inhaled corticosteroid (ICS) therapy in chronic obstructive pulmonary disease (COPD), with levels ≥300 cells/µL associated with greater treatment benefit. However, the prevalence of elevated BEC in Malaysian COPD populations is not well defined. We evaluated the prevalence and persistence of BEC ≥300 cells/µL in a real-world COPD cohort in Sabah.
We performed a retrospective review of COPD patients managed under respiratory services in Queen Elizabeth Hospital, Sabah. BEC values were obtained from full blood count (FBC) records. The primary outcome was the prevalence of BEC ≥300 cells/µL among patients with at least one available FBC. Persistence was assessed in patients with ≥2 FBC measurements ≥3 months apart and classified as persistent (≥300 on all measurements), intermittent (≥300 on at least one measurement), or never (<300 on all measurements).
Among 210 spirometry-confirmed COPD patients, 179 (85.2%) had at least one FBC recorded. BEC ≥300 cells/µL occurred in 114/179 (63.7%, 95% CI 56.4–70.4). Serial FBC suitable for persistence analysis was available in 108/210 (51.4%), with repeat testing <3 months apart being the most common limitation. In this serial cohort, median age was 66 years (IQR 61–74) and 71.3% were male. Persistent eosinophilia occurred in 47/108 (43.5%, 95% CI 34.6–52.9), intermittent eosinophilia in 32/108 (29.6%), and no eosinophilia in 29/108 (26.9%). Based on highest recorded BEC, eosinophil ranges were 300–500 cells/µL in 32/108 (29.6%), 500–1000 cells/µL in 33/108 (30.6%), and >1000 cells/µL in 15/108 (13.9%).
Blood eosinophilia ≥300 cells/µL was common in this Sabah COPD cohort, and nearly half of patients with serial measurements demonstrated persistent eosinophilia, supporting routine eosinophil monitoring for biomarker-guided COPD management.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
COPD, Airway smooth muscle, Inflammation
maximum 3 keywords and no abbreviations, separated by commas
We thank the Respiratory Unit and Medical Records Department of Hospital Queen Elizabeth, Kota Kinabalu, for their support in data access.
302